Author

Sharmila Koppisetti

Observed name: S. Koppisetti

Institution: Celularity (United States)

Observed institution: Celularity (United States)

ORCID: 0009-0009-1993-806X

Observed ORCID: 0009-0009-1993-806X

OpenAlex ID: A5061897008

Senescence, NK cells, and cancer: navigating the crossroads of aging and disease

2025 · Marina Gergues, Rafijul Bari, et al. · Frontiers in Immunology · 47

Human Placenta‐Derived Cells ( PDA ‐002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi‐Center, Randomised, Double‐Blind, Placebo‐Controlled Trial

2025 · Richard Pollak, James Anderson, et al. · International Wound Journal · 10

Results of Cynk-001-AML-001: A Phase I Multi-Dose Study Evaluating the Safety, Tolerability, and Persistence of Cynk-001 in Adults with De Novo or Secondary Acute Myeloid Leukemia in Morphologic Complete Remission with Minimal Residual Disease or Relapsed/Refractory AML

2023 · James McCloskey, Hongtao Liu, et al. · Blood · 6

Abstract CT201: Early report of a phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 (NCT04365101)

2021 · Corey Casper, Leonid Groysman, et al. · Cancer Research · 5

Nanomedicine in Demyelinating Disease Application to Diagnosis and Therapy in Multiple Sclerosis

2024 · Mariia Bilorosiuk, Lawrence Steinman, et al. · Springer eBooks · 2

A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

2023 · Martin Gutierrez, Darren Sigal, et al. · Journal of Clinical Oncology · 2

A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM).

2022 · Daniela Annenelie Bota, Behnam Badie, et al. · Journal of Clinical Oncology · 2

Rtid-07. Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (cynk-001) for Treatment of Recurrent Glioblastoma

2020 · Nazanin Majd, Maha Rizk, et al. · Neuro-Oncology · 2

Ps1215 Safety and Tolerability of Allogeneic, Off‐the Shelf Placental Natural Killer Cells (pnk 007) in Phase 1 Multiple Myeloma and Acute Myeloid Leukemia Studies (nct02955550 and Nct02781467)

2019 · S. Koppisetti, C. Balint, et al. · HemaSphere · 1

Mesenchymal stem cell therapy for skin repair and rejuvenation

2026 · Irene Raitman, Lin Kang, et al. · Discover Immunity.

Works count: 10

Citation count: 77

H-index: 4

I10-index: 2